Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus CapeOX or FOLFIRI versus chemotherapy alone for advanced colorectal cancer
ChiCTR1800018013Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in colorectal cancer (CRC) (2 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800018013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018013.